Information Provided By: 
Fly News Breaks for February 3, 2016
CELG, AMGN, GILD
Feb 3, 2016 | 08:57 EDT
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
News For GILD;AMGN;CELG From the Last 2 Days
AMGN
Apr 15, 2024 | 07:22 EDT
TD Cowen lowered the firm's price target on Amgen to $360 from $370 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 earnings based on their sales/scrip trackers and to better align estimates with Q1 and 2024 sales and operating expenses guidance.
